Q-omics provides the consensus-scored RAB5B profile across patient tissues and cancer cell-line models. RAB5B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB5B is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, RAB5B protein abundance shows 29,250 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where RAB5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB5B survival associations across molecular data types. RAB5B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB5B RNA expression–survival associations across cancer types. High RAB5B expression shows unfavorable associations in KICH, SCLC and ACC, but favorable associations in KIRC, LGG and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB5B RNA expression.
This table summarizes RAB5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB5B shows lower tumor expression in COAD, READ, LUAD and KICH and higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher RAB5B RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with RAB5B in patient tissues and cancer cell lines. In patient samples, RAB5B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
